Celltrion Calls For Harmonized Approach To ‘Biobetters’
As Latest Data Shows Benefits Of Subcutaneous Infliximab Biosimilar Remsima SC
• By David Wallace
Celltrion has highlighted divergent approaches to biobetters • Source: ferhat ozyurt / Alamy Stock Photo 
